Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health
innovation, today announced Ovaprene’s inclusion in a presentation
to physicians on the latest forms of novel contraception. Ovaprene
is Daré’s clinical stage, non-hormonal vaginal ring designed to
provide multiple weeks of contraceptive protection. The
presentation entitled, “Contraception 2019: What about LARC, Rings,
Gel, even Apps?”, was given by noted physician and women’s health
expert Dr. James A. Simon during the Survival Skills for Today’s
Gynecologist continuing medical education conference in New York
City on Sunday, April 14th. In Dr. Simon’s presentation, Ovaprene
was identified as a promising new method of contraception in
clinical development based on its first-in-category potential as a
non-hormonal, monthly birth control ring for women, and a product
to watch in 2019 given that topline data from Ovaprene’s postcoital
test (PCT) clinical trial is expected later this year.
“The ’survival skills’ forum provides an opportunity to present
on a variety of important topics related to gynecological health
and wellness, including emerging novel contraceptive methods,” said
James A. Simon, MD, President and Medical Director of IntimMedicine
Specialists®, Clinical Professor at George Washington University
School of Medicine, and current President of the International
Society for the Study of Women’s Sexual Health. “Since hormonal
birth control can impact a woman’s sexual functioning, a monthly
non-hormonal option like Ovaprene has the potential to serve as a
viable contraceptive that is both convenient and effective for
women in need of new non-hormonal therapies.”
Topline data from the Ovaprene PCT trial are expected in the
second half of 2019. In a previous PCT trial, Ovaprene successfully
prevented sperm from reaching the cervical canal.1 The
ongoing PCT clinical trial sponsored by Daré and supported by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, is designed to assess general safety, acceptability,
and effectiveness in preventing most progressively motile sperm
from reaching the cervical canal following intercourse, which is
considered indicative of contraceptive effectiveness. If the
PCT clinical trial demonstrates that Ovaprene is effective in
preventing most progressively motile sperm from progressing into
the cervical canal and is safe to use over multiple weeks, then
Daré intends to prepare and file an Investigational Drug Exemption
(IDE) with the FDA to commence a pivotal clinical study with
Ovaprene in 2020.
“Dr. Simon’s presentations at the Survival Skills conference
highlighted the continued, persistent unmet needs across a variety
of women’s health conditions and the challenges women are facing
when it comes to finding new and effective non-hormonal solutions,”
said Sabrina Martucci Johnson, President and CEO of Daré
Bioscience, Inc. “As the potentially first and only non-daily and
non-implanted, hormone-free product in the category, Ovaprene has
the potential to be an important and disruptive new entrant into a
marketplace that has not seen a great deal of recent
innovation. A non-hormonal contraceptive can also play an
important role in preserving women’s sexual functioning.”
A review of recent studies pertaining to oral contraceptives and
female sexual dysfunction published in Sexual Medicine Reviews, an
official journal of the International Society for Sexual Medicine,
linked the use of oral hormonal contraception to increased sexual
dysfunction in women.2 In addition to Ovaprene, Daré is
developing Sildenafil Cream, 3.6%, a product candidate containing
the same active ingredient in Viagra® that is being developed for
the treatment of female sexual arousal disorder.
- Journal of Reproductive Medicine 2009; 54:
685-690
-
https://www.smr.jsexmed.org/article/S2050-0521(16)30022-1/pdf
About Ovaprene®
Ovaprene is a novel vaginal ring that has the potential to
become the first hormone-free monthly contraceptive approved by the
U.S. Food and Drug Administration (FDA). Ovaprene’s once-a-month
format is designed to provide multiple weeks of contraceptive
protection for the growing number of women seeking convenient,
non-hormonal methods. In May 2018, a post-coital test (PCT)
clinical trial was initiated to assess the safety and efficacy of
Ovaprene in women over multiple weeks of use. Daré anticipates
reporting topline data results from the PCT clinical trial in the
second half of 2019. If safety and effectiveness are demonstrated
in the ongoing PCT clinical trial, Daré intends to prepare and file
an Investigational Device Exemption with the FDA to commence a
single pivotal clinical trial. This pivotal trial would be expected
to support marketing approvals of Ovaprene in the U.S., the EU, and
other regions worldwide.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
health. The company’s mission is to identify, develop and bring to
market a diverse portfolio of differentiated therapies that expand
treatment options, improve outcomes and facilitate convenience for
women, primarily in the areas of contraception, vaginal health,
sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category
candidates in clinical development: Ovaprene, a non-hormonal,
monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use
these channels to distribute material information about the
company, and may also use social media to communicate important
information about the company, its finances, product candidates,
clinical trials and other matters. The information Daré posts
on its investor relations website or through social media channels
may be deemed to be material information. Daré encourages
investors, the media, and others interested in the company to
review the information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Forward-Looking Statements
Daré cautions you that all statements, other than statements of
historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” "project,” “target,” “tend to,” or the negative
version of these words and similar expressions. Such statements
include, but are not limited to, statements relating to Ovaprene’s
potential to achieve regulatory approval and become a
first-in-category contraceptive product, the timing of results from
and commencement of clinical studies of Ovaprene, and the potential
for a single pivotal clinical trial to support marketing approvals
of Ovaprene in the U.S., the EU, and other jurisdictions.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Daré’s actual
results, performance or achievements to be materially different
from future results, performance or achievements expressed or
implied by the forward-looking statements in this press release,
including, without limitation, risk and uncertainties related to:
Daré’s ability to raise additional capital when and as needed, to
advance its product candidates; Daré’s ability to develop, obtain
regulatory approval for, and commercialize its product candidates;
the failure or delay in starting, conducting and completing
clinical trials or obtaining FDA or foreign regulatory
approval for Daré’s product candidates in a timely manner; Daré’s
ability to conduct and design successful clinical trials, to enroll
a sufficient number of patients, to meet established clinical
endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its
product candidates; Daré’s ability to retain its licensed rights to
develop and commercialize a product candidate; Daré’s ability to
satisfy the monetary obligations and other requirements in
connection with its exclusive, in-license agreements covering the
critical patents and related intellectual property related to its
product candidates; developments by Daré’s competitors that make
its product candidates less competitive or obsolete; Daré’s
dependence on third parties to conduct clinical trials and
manufacture clinical trial material; Daré’s ability to adequately
protect or enforce its, or its licensor’s, intellectual property
rights; the lack of patent protection for the active ingredients in
certain of Daré’s product candidates which could expose its
products to competition from other formulations using the same
active ingredients; the risk of failure associated with product
candidates in preclinical stages of development that may lead
investors to assign them little to no value and make these assets
difficult to fund; and disputes or other developments concerning
Daré’s intellectual property rights. Daré’s forward-looking
statements are based upon its current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. All forward-looking statements are expressly qualified
in their entirety by these cautionary statements. For a detailed
description of Daré’s risks and uncertainties, you are encouraged
to review its documents filed with the SEC including
Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Daré undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
Investors on behalf of Daré Bioscience, Inc.: Alex Gray
Burns McClellan agray@burnsmc.com 212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.: Amanda Guisbond
Canale Communications amanda@canalecomm.com 781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024